Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
advanced breast cancer, HR+/HER2, MONALEESA-3 study, fulvestrant + ribociclib, significant improvement in PFS
Advertisement